MC-19PD1 CAR-T cell therapy (Peking University)

N/A

Report date: 2024/11/22 20:00:28

Base Information

Drug NameMC-19PD1 CAR-T cell therapy (Peking University)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaPending

Originator CompaniesPeking University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPeking University

Active IndicationsN/A

Inactive IndicationsLymphoma

Other Information

ATC CodeN/A